Back to Main Menu
Products & Services
Digital Pathology Biomarkers
Cancer diagnosis relies heavily on the practice of pathology, traditionally depending on human interpretations of tissue patterns and morphology. The process is subjective, slow, and in some cases error-prone. With an increasing numbers of cancer patients and shortage of pathologists globally, there is a greater need for technical innovations to improve efficiency and objectivity in pathology analysis. However, in the era of artificial intelligence, we believe its possible to go beyond improving efficiency to harnessing new forms of data driven tumor biomarker detection to improve cancer treatment significantly. MBM is focused on the clinical development of advanced image analysis technology to pioneer these new diagnostic possibilities in prognosis and companion diagnosis.
Our Nucleotyping software quantitatively analyses the chromatin structure in tumor nuclei, which reflect epigenetic modification of DNA and ultimately gene expression. This analysis results in a biomarker measurement termed as chromatin value that is used to classified tumors as homogeneous or heterogeneous. This biomarker has been clinically verified as a pan-cancer prognostic biomarker for colorectal, prostate, gynecological and lung cancers.
*Nucleotyping was licensed from Room4 (UK), and originally developed by the Institute of Cancer Genomics and Informatics (Norway).
Lancet Oncology 2018, 19: 356-369.
Br J Cancer. 2016 May 24;114(11):1243-50.
The Ploidy Work Station performs automated quantitative analysis of chromosome copy number in tumor cells. Abnormalities of cellular DNA content (polyploidy and aneuploidy) have long been associated with tumorigenesis and recently associated with immune response modulation. DNA ploidy status is a clincally verified prognostic biomarker in colorectal, prostate and gynecological cancers.
*Ploidy Work Station was licensed from Room4 (UK), and originally developed by the Institute of Cancer Genomics and Informatics (Norway).
Br J Cancer. 2014 Apr 15;110(8):2159-64.
Gynecol Oncol. 2017 Sep;146(3):596-602.
Nat Rev Clin Oncol. 2016 May;13(5):291-304
Fully automated quantitative analysis of tumor tissue-microenvironment ratio. Stroma measures degree of stroma invasion surrounding cancer cells. Tumor stroma is comprised of cancer-associated fibroblast, endothelial cell, myloid cell, pericyte, lymphocyte and extra-cellular matrix. Its plays an important role in tumorigenesis, tumor invasion and metastasis, and is a clinically verified biomarker for patient prognosis in colorectal and prostate cancer.
*Stroma was licensed from Room4 (UK), and originally developed by the Institute of Cancer Genomics and Informatics (Norway).
Coloprog is a method that combines DNA ploidy and stroma content biomarkers to create a risk profile for each patient. ColoProg has been validated in more than 3000 colorectal cancer patients. *Coloprog was licensed from Oxford Cancer Biomarkers (UK), and originally developed by the Institute of Cancer Genomics and Informatics (Norway).
Int J Cancer. 2020 Aug 15;147(4):1228-1234.
Br J Cancer. 2020 Sep;123(6):973-981.
Annals of Oncology 2018, 29: 616-623.
Latest Blog Posts
News and healthcare tips
MBMbio announced residency at JLABS @ ShanghaiDecember 1, 2021Shanghai China, December 1, 2021 – MBMbio announced today that, effective...
The Often Neglected Red Blood Cell Offers a Breakthrough in Liquid Biopsy Technology for Early Stage Cancer Detection
MBM’s “Colorectal Cancer Recurrence Risk Assessment Marker” announced at the National Colorectal Surgery Symposium
MBM recognized as a Top 30 enterprise in the 2020 National Innovation & Entrepreneurship Competition